Review of ampligen clinical trials in chronic fatigue syndrome

All male patients agree not to be a sperm donor and to use an effective means of contraception while on study medication and until 90 days after the last study medication infusion.

The KPS must be rounded in increments of ten Ability to provide written informed consent indicating awareness of the investigational nature of this study. Documentation during baseline of a normal T4 or other laboratory evidence that subject is euthyroid is also required. The patient must also have at least one of the following "Long Hauler" symptoms which must have persisted or recurred during 3 or more consecutive months of illness and must not have preceded the onset of the COVID symptoms fever or chills, cough, shortness of breath or difficulty breathing, new loss of taste or smell or chest pain.

Exclusion Criteria: Inability to return for scheduled treatment and assessments. Chronic or intercurrent acute medical disorder or disease making implementation or interpretation of the protocol or results difficult or unsafe. Pregnant or lactating females. Therapy with interferons, interleukins, or other cytokines or investigational drugs within 6 weeks of beginning study medication. Subjects must give written informed consent prior to discontinuation of investigational drugs. Contacts and Locations.

Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials. Layout table for location contacts Contact: Diane Young diane. Lapp, M. Hunter-Hopkins Center, P. More Information. Additional Information: research. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.

PLoS One. Epub Mar Expert Rev Clin Pharmacol. Hunter-Hopkins Center, P. Ampligen is a step toward effective treatment. Klimov VV. From basic to clinical immunology. Ann Intern Med. Actively scan device characteristics for identification. Use precise geolocation data. Select personalised content. Create a personalised content profile.

Measure ad performance. Select basic ads. Create a personalised ads profile. Select personalised ads. Apply market research to generate audience insights. Measure content performance. Develop and improve products. More Information. Publications automatically indexed to this study by ClinicalTrials. PLoS One. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.

Epub Mar National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Chronic Fatigue Syndrome Myalgic Encephalomyelitis. Drug: Ampligen. Phase 3. Study Type :. Interventional Clinical Trial. Enrollment :. Study Start Date :. Actual Primary Completion Date :.